Payment overview · 2025
General Payments
$468.06
22 reported records · 4 companies
Healthcare provider profile · identity verified
Jamie Dost Harrison, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CAPE GIRARDEAU, MO · NPI 1922260280
Verified facts
What the public records show
CMS Open Payments records show Jamie Dost Harrison, M.D. received $468.06 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Arexvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $228.20 | 48.8% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.97 | 21.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.76 | 16.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.13 | 14.1% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $468.06 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $228.20 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.76 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.44 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.75 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.18 | 7 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
77 | 77 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 245 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 229 | 61 |
| Lisinopril | Lisinopril | 218 | 61 |
| Omeprazole | Omeprazole | 201 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 50 |
| Metformin Hcl | Metformin Hcl | 148 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 35 |
| Montelukast Sodium | Montelukast Sodium | 128 | 33 |
| Gabapentin | Gabapentin | 126 | 33 |
| Losartan Potassium | Losartan Potassium | 117 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 22 |
| Alendronate Sodium | Alendronate Sodium | 79 | 26 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 77 | 77 |
| Alprazolam | Alprazolam | 75 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 18 |
| Trazodone Hcl | Trazodone Hcl | 71 | 18 |
| Ezetimibe | Ezetimibe | 70 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 13 |
| Sertraline Hcl | Sertraline Hcl | 56 | 12 |
| Bupropion Xl | Bupropion Hcl | 51 | 12 |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Meloxicam | Meloxicam | 42 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 11 |
| Simvastatin | Simvastatin | 39 | 12 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 21 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $468.06 · 22 records | Amgen Inc. | AREXVY, BEXSERO, CREON, OTEZLA, Ozempic, PENMENVY, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error